IFN‐γ has been reported to be associated with cancer immunity, and enhancing its reactivity is crucial for overcoming resistance to immunotherapy.[33] An impaired IFN‐γ response leads to diminished tumor antigen presentation and reduced PD‐L1 expression and subsequently contributes to primary resistance against PD‐1 blockade therapies.[34, 35] Upon investigating the mRNA targets of YTHDF1 based on proteomics and RIP‐seq data, we discovered that YTHDF1 directly binds to the m6A‐modified site within the protein‐coding region of IRF1 mRNA, consequently triggering its degradation. The gene discussed is YTHDF1; the disease is cancer.